Indivior Ordinary Shares logo
INDVIndivior Ordinary Shares
Trade INDV now
Indivior Ordinary Shares primary media

About Indivior Ordinary Shares

Indivior (LSE:INDV), (NASDAQ:INDV) is a pharmaceutical company focused on developing medications to treat addiction and serious mental illnesses. Their work is centered around providing innovative solutions to individuals suffering from opioid dependence, alcohol dependence, and schizophrenia, among other conditions. Their portfolio includes both marketed therapies and a pipeline of products at various stages of development, aimed at addressing unmet medical needs within these therapeutic areas. Indivior operates with the mission to transform addiction from a global human crisis to a recognized and treated chronic disease, striving to expand access to treatment and to support patients in reclaiming their lives. Their commitment to patient-centric healthcare is evident in their ongoing research and development efforts, as well as their educational and support initiatives for patients and healthcare providers.

What is INDV known for?

Snapshot

Public US
Ownership
2014
Year founded
1244
Employees
Virginia, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Indivior Ordinary Shares

  • Addiction Treatment Drugs: Indivior develops, manufactures, and commercializes medications for treating opioid dependence and alcohol dependence. Their most well-known product is Suboxone, a medication used to manage opioid dependence.
  • Clinical Trials: They conduct clinical trials to evaluate the safety and efficacy of their drug candidates in various stages of development.
  • Regulatory Affairs: They work with regulatory agencies to obtain marketing approval for their drugs, allowing them to be prescribed to patients.
  • Partnerships and Collaborations: Indivior may collaborate with other pharmaceutical companies or research institutions to leverage expertise and resources for broader development and commercialization of their drugs.
  • Manufacturing and Supply Chain: While not directly involved in large-scale manufacturing, they partner with other companies to ensure the quality and supply of their drugs if they reach the market.
  • Access and Affordability Programs: Indivior may implement programs to improve access and affordability of their medications for patients, particularly those in underserved communities.

Indivior Ordinary Shares executive team

  • Mr. Joseph J. CiaffoniCEO & Director
  • Mr. Ryan PreblickChief Financial Officer
  • Mr. Vishal KaliaChief Strategy & Operating Officer
  • Dr. Christian HeidbrederChief Scientific Officer
  • Mr. Jason ThompsonVice President of Investor Relations
  • Mr. Jeffrey W. Burris J.D.Chief Legal Officer
  • Mr. Kevin L. EspinozaChief Integrity & Compliance Officer
  • Ms. Angela Colon-Mahoney M.S.Chief Human Resources Officer
  • Mr. Hillel WestChief Manufacturing & Supply Officer
  • Mr. Patrick A. BarryChief Commercial Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.